Download MendeleySmall Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).
De Lucca, G.V., Shi, Q., Liu, Q., Batt, D.G., Beaudoin Bertrand, M., Rampulla, R., Mathur, A., Discenza, L., D'Arienzo, C., Dai, J., Obermeier, M., Vickery, R., Zhang, Y., Yang, Z., Marathe, P., Tebben, A.J., Muckelbauer, J.K., Chang, C.J., Zhang, H., Gillooly, K., Taylor, T., Pattoli, M.A., Skala, S., Kukral, D.W., McIntyre, K.W., Salter-Cid, L., Fura, A., Burke, J.R., Barrish, J.C., Carter, P.H., Tino, J.A.(2016) J Med Chem 59: 7915-7935
- PubMed: 27531604
- DOI: https://doi.org/10.1021/acs.jmedchem.6b00722
- Primary Citation of Related Structures:
5JRS - PubMed Abstract:
Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous autoimmune diseases. This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clinical development.
Organizational Affiliation:
Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development , P.O. Box 4000, Princeton, New Jersey 08543, United States.
